Abstract
We studied the association between bisphosphonate use and risk of gastrointestinal (GI) cancers in a nationwide retrospective cohort from Denmark. All users of bisphosphonates and other drugs against osteoporosis between 1996 and 2006 (n = 103,562) were used as the exposed group, with three age- and gender-matched controls from the general population (n = 310,683) as the nonexposed group. The main outcome was occurrence of cancer of the esophagus, ventricle, small intestine, colon, pancreas, gallbladder or bile duct, or liver. Except for colon cancer, most of the GI cancers were rare. For clodronate and raloxifene, no excess risk was present for any of the GI cancers. For alendronate, an excess risk of esophageal and liver cancer was observed; however, the excess risk was most pronounced at low doses and short duration of observation. No dose–response relationship was present except for colon cancer with alendronate, where a decrease was seen with increasing dose so that at high doses a seemingly protective effect was present (≥1 defined daily dose, HR = 0.29, 95% CI 0.14–0.62). For etidronate, an excess risk of esophageal, liver, pancreas, and gallbladder and bile duct cancers was seen. Again, no relationship with dose or duration of observation was present. An excess risk of esophageal and liver cancers may be seen with alendronate and etidronate. However, the association may not be causal as no dose–response or time relationship was present. For colon cancer, the decline with increasing alendronate dose may be due to a “healthy user” effect.
Similar content being viewed by others
References
Wysowski DK (2009) Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 360:89–90
Terashima T, Hiramatsu K, Shimatani A, Matsuda M, Ogino H, Satomura Y, Noda Y (2006) An esophageal ulcer mimicking advanced esophageal cancer in a patient on alendronate sodium treatment for osteoporosis. Endoscopy 38(2):E37
Ribeiro A, DeVault KR, Wolfe JT, Stark ME (1998) Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc. 47:525–528
de Groen P, Lubbe D, Hirsch L, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick M, Pinkas H, Wang K (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016–1021
Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JFJ (1995) The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 274:474–477
Lagergren J, Bergström R, Lindgren A, Nyrén O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340:825–831
Lassen A, Hallas J, de Muckadell OBS (2006) Esophagitis: incidence and risk of esophageal adenocarcinoma—a population-based cohort study. Am J Gastroenterol 101:1193–1199
Cardwell CR, Abnet CC, Cantwell MM, Murray LJ (2010) Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304:657–663
Nguyen DM, Schwartz J, Richardson P, El-Serag HB (2010) Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Dig Dis Sci 55:3404–3407
Solomon DH, Patrick A, Brookhart MA (2009) More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 360:1789–1792
Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095–1102
Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V (2010) Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case–control analysis within a UK primary care cohort. BMJ 341:c4444
Sewing L, Steinberg F, Schmidt H, Göke R (2008) The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 13:782–789
Montella L, Addeo R, Palmieri G, Caraglia M, Cennamo G, Vincenzi B, Guarrasi R, Mamone R, Faiola V, Frega N, Capasso E, Maiorino L, Leopardo D, Pizza C, Montesarchio V, Del Prete S (2010) Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series. Cancer Chemother Pharmacol 65:1137–1143
Penel N, Dewas S, Doutrelant P, Clisant S, Yazdanpanah Y, Adenis A (2008) Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis. Support Care Cancer 16:387–392
Andersen T, Madsen M, Jørgensen J, Mellemkjær L, Olsen J (1999) The Danish National Hospital Register. Dan Med Bull 46:263–268
Mosbech J, Jørgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen T (1995) The Danish National Patient Register: evaluation of data quality [in Danish]. Ugeskr Laeger 157:3741–3745
Lévesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340:b5087
Bagnardi V, Blangiardo M, La Vecchia C, Corrao G (2001) Alcohol consumption and the risk of cancer: a meta-analysis. Alcohol Res Health 25:263–270
Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ (2011) Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol 106:1340–1350
Carroll C, Cooper K, Papaioannou D, Hind D, Pilgrim H, Tappenden P (2010) Supplemental calcium in the chemoprevention of colorectal cancer: a systematic review and meta-analysis. Clin Ther 32:789–803
Curtis JR, Larson JC, Delzell E, Brookhart MA, Cadarette SM, Chlebowski R, Judd S, Safford M, Solomon DH, Lacroix AZ (2011) Placebo adherence, clinical outcomes, and mortality in the women’s health initiative randomized hormone therapy trials. Med Care 49:427–435
Acknowledgement
This study was funded by an unrestricted grant from the A. P. Møller Foundation (Fonden til Lægevidenskabens Fremme), Servier Denmark, and the Dandy Foundation. None of the sponsors had any role in obtaining data, analyzing data, or writing the report.
Author information
Authors and Affiliations
Corresponding author
Additional information
The author has stated that there is no conflict of interest.
Rights and permissions
About this article
Cite this article
Vestergaard, P. Occurrence of Gastrointestinal Cancer in Users of Bisphosphonates and Other Antiresorptive Drugs Against Osteoporosis. Calcif Tissue Int 89, 434–441 (2011). https://doi.org/10.1007/s00223-011-9539-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-011-9539-4